Free Trial
NASDAQ:ACRS

Aclaris Therapeutics Q1 2025 Earnings Report

Aclaris Therapeutics logo
$1.63 +0.06 (+3.82%)
Closing price 04:00 PM Eastern
Extended Trading
$1.60 -0.03 (-2.09%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aclaris Therapeutics EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.19
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Aclaris Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.55 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aclaris Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
7:00AM ET

Aclaris Therapeutics Earnings Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Aclaris Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aclaris Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclaris Therapeutics and other key companies, straight to your email.

About Aclaris Therapeutics

Aclaris Therapeutics (NASDAQ:ACRS) a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

View Aclaris Therapeutics Profile

More Earnings Resources from MarketBeat